

REMARKS/ARGUMENTS

With entry of the instant amendment, new claims 20-22 have been added. Claims 1, 2, 8-16, 18, 19, and 20-22 are therefore pending and under examination.

Claims 1, 2 and 8-16 are allowed; claims 18 and 19 are rejected.

The amendment to add new claims 20-22 adds no new matter. Support can be found, *e.g.*, in claims 1 and 2 as filed.

The amendments to allowed claims 1 and 2 add no new matter and are made so that the language setting out the Markush groups is consistent with the language in amended claim 18.

The amendment to claim 18 adds no new matter. Support can be found, *e.g.*, in claim 1 as filed.

Applicants thank the Examiner for indicating that claims 1, 2, 8-16, 18, and 19 are allowable and for the phone calls on May 29, 2008, and June 5, 2008 in which the Examiner indicated that the method claims would likely be allowable and discussed issues relating to the search of the compositions set forth in claim 18.

Rejection under 35 U.S.C. § 102(b) or, alternatively 35 U.S.C. § 103

Claims 18 and 19 are rejected as anticipated by, or in the alternative, obvious over Napier et al., *Proc. Roy. Soc. Med.* 15:44-45, 1922 ("Napier"). The Examiner characterizes Napier as teaching a compound, acetyl-para-aminophenyl-stibiato, that was administered for the treatment of Kala-azar (leishmaniasis). The Examiner further contends that it would have been obvious to include an excipient in the pharmaceutical compositions (claim 19).

In the interests of expediting prosecution, claim 18 has been amended to explicitly recite the elements that characterize the compounds comprised by the pharmaceutical compositions. The compounds encompassed by amended claim 18, relative to those set forth in claim 1, do not have an NR¹⁷R¹⁸ relating to the Markush groups for the R¹⁴, R¹⁵ and R¹⁶ substituents. Napier therefore does not anticipate claim 18.

Napier also does not render claim 18 obvious, as the only compound disclosed by Napier has an amine linkage at one of the positions R¹⁴, R¹⁵ or R¹⁶. There is no teaching or suggestion in Napier or that the Examiner points to elsewhere in the art that would lead one to a compound without the amine linkage as currently claimed. Claim 19 is also patentable over the art for the same reason.


In view of the foregoing, Applicants respectfully request withdrawal of this rejection.

CONCLUSION

Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jean M. Lockyer
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:jml
61505607 v1